A case of insulinoma with hypoglycemia that was better managed with lanreotide than octreotide. Issue 5 (19th May 2021)

• Record Type: Journal Article
• Authors: Yamaoka, Keiko; Nagashima, Shuichi; Okada, Nobukazu; Sawayama, Nagisa; Saito, Shinsuke; Takahashi, Manabu; Okada, Kenta; Endo, Kazuhiro; Koizumi, Masaru; Sasanuma, Hideki; Ebihara, Ken; Kasajima, Atsuko; Fukushima, Noriyoshi; Sata, Naohiro; Ishibashi, Shun
• Is Part Of: Clinical case reports. Volume 9:Issue 5(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-05-19
• Subjects: hypoglycemia -- insulinoma -- lanreotide -- octreotide -- somatostatin analog; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.4118
• Languages: English
• ISSNs: 2050-0904

Abstract

Abstract: Long‐acting somatostatin analogs, including lanreotide slow release (LAN‐SR) and octreotide long‐acting release (OCT‐LAR), can improve hypoglycemia in insulinoma. LAN‐SR may be more beneficial in some patients with insulinoma than OCT‐LAR. Abstract : Long‐acting somatostatin analogs, including lanreotide slow release (LAN‐SR) and octreotide long‐acting release (OCT‐LAR), can improve hypoglycemia in insulinoma. LAN‐SR may be more beneficial in some patients with insulinoma than OCT‐LAR.